CMB Stock Overview
A clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Cambium Bio Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.42 |
| 52 Week High | AU$1.60 |
| 52 Week Low | AU$0.30 |
| Beta | 0 |
| 1 Month Change | -22.02% |
| 3 Month Change | 8.97% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| CMB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 3.7% | 1.1% | -1.0% |
| 1Y | n/a | 4.6% | 8.5% |
Return vs Industry: Insufficient data to determine how CMB performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how CMB performed against the Australian Market.
Price Volatility
| CMB volatility | |
|---|---|
| CMB Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: CMB's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: CMB's weekly volatility has decreased from 21% to 13% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Karolis Rosickas | www.cambium.bio |
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. Its lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus for wound healing indications.
Cambium Bio Limited Fundamentals Summary
| CMB fundamental statistics | |
|---|---|
| Market cap | AU$5.07m |
| Earnings (TTM) | AU$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMB income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$0 |
| Earnings | AU$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CMB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 23:46 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cambium Bio Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|